Skip to main content
TipRanks
Go Ultimate75% OFF

Aptamer Group Plc (APTA) AI Stock Analysis

12 Followers
GB:APTA

Aptamer Group Plc

(LSE:APTA)

Select Model
Rating:40Underperform
Price Target:GBX 0.27â–¼(-4.91% Downside)
Action:reiterated
Date:11/13/26

Aptamer Group scores low primarily because of its financial profile: persistent operating losses, a cost base around twice revenue, and £2.30m of free cash outflow keep the business reliant on equity funding, with dilution risk if revenue does not scale. Offsetting positives are a rebuilt, essentially debt-free balance sheet (£5.74m equity, £0.17m debt), two consecutive years of revenue growth to £1.54m, and improving gross margin. Technically, a recent bounce above the 20- and 50-day averages is encouraging but the stock remains far below its 200-day average and is now overbought, while negative earnings and no dividend leave valuation unsupportive.

Positive Factors
Stronger Balance SheetThe materially higher equity base and very low leverage provide a stronger financial cushion than in prior years. This reduces balance-sheet strain and gives Aptamer greater flexibility to continue developing its platform, although operating losses still limit that protection.
Negative Factors
Persistent Operating LossesDeep and persistent losses show that current revenue is not yet sufficient to absorb Aptamer’s operating cost base. The very negative net margin leaves little room for execution setbacks and means a durable improvement in scale or cost efficiency is still required before profitability can emerge.

Aptamer Group Plc (APTA) vs. iShares MSCI United Kingdom ETF (EWC)

-80%-60%-40%-20%0%20%40%GB:APTA-65.24%EWC+8.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
GBP 9.88M
Dividend Yield
―
Average Volume (3M)
6.06M
Price to Earnings (P/E)
-9.5
Beta (1Y)
0.96
Revenue Growth
28.35%
EPS Growth
50.00%
Country
UK
Employees
34
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Aptamer Group Plc Business Overview & Revenue Model

Company Description

Aptamer Group plc, an international company headquartered in York, United Kingdom, specializes in providing advanced binders for applications spanning research, diagnostics, and therapeutics. Their innovative binder technology is engineered to resolv...

Aptamer Group Plc Financial Statement Overview

Summary

Financials remain weak overall. Revenue grew for a second straight year to £1.54m and gross margin improved to 37.1%, but the cost base is still roughly double sales, producing a £2.85m operating loss and a deeply negative return on equity. Free cash outflow widened to £2.30m and the company has never generated positive operating cash, leaving it dependent on external funding. The one clear strength is the recapitalised balance sheet: equity rebuilt to £5.74m with debt cut to a negligible £0.17m, giving an essentially debt-free structure that buys time but not self-sufficiency.

Income Statement

22Negative

Balance Sheet

58Neutral

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMJun 2025Jun 2024Jun 2023Jun 2022Jun 2022
Income Statement
Total Revenue1.54M1.54M1.20M860.00K4.04M1.75M
Gross Profit573.00K573.00K350.00K250.00K2.69M359.00K
EBITDA-2.60M-2.60M-2.28M-2.81M-2.20M-7.36M
Net Income-1.86M-1.86M-2.42M-2.96M-2.09M-7.84M
Balance Sheet
Total Assets7.18M7.18M2.83M2.77M11.52M2.75M
Cash, Cash Equivalents and Short-Term Investments4.36M4.36M1.06M870.00K6.69M234.00K
Total Debt170.00K170.00K491.00K817.00K1.31M1.08M
Total Liabilities1.44M1.44M1.45M1.88M3.47M2.45M
Stockholders Equity5.74M5.74M1.38M887.00K8.05M304.00K
Cash Flow
Free Cash Flow-2.30M-2.30M-2.01M-2.41M-2.79M-6.09M
Operating Cash Flow-2.13M-2.13M-2.00M-2.28M-2.38M-4.06M
Investing Cash Flow-253.00K-253.00K-92.00K-122.00K-418.00K-2.03M
Financing Cash Flow5.68M5.68M2.28M3.04M9.12M-365.00K

Aptamer Group Plc Technical Analysis

Technical Analysis SentimentNegative
Last Price0.28

Price Trends

50DMA0.32Negative
100DMA0.37Negative
200DMA0.52Negative

Market Momentum

MACD-0.00Negative
RSI39.97Neutral
STOCH33.33Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:APTA, the sentiment is Negative. The current price of 0.28 is below the 20-day moving average (MA) of 0.30, below the 50-day MA of 0.32, and below the 200-day MA of 0.52, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 39.97 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:APTA.

Aptamer Group Plc Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:APTA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:BVXPGB:BVXP89OutperformGBP 101.88M13.4567.81%7.69%-1.10%0.32%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:APTAGB:APTA40UnderperformGBP 9.88M-9.50-46.61%―28.35%50.00%
GB:AVCTGB:AVCT40UnderperformGBP 287.20M-6.47-1293.07%―――
GB:FABGB:FAB40UnderperformGBP 5.32M-4.29-97.87%―7.38%44.13%
GB:OBDGB:OBD40UnderperformGBP 14.11M-0.26-451.74%―33.37%86.41%
GB:ARECGB:AREC33UnderperformGBP 32.39M143.003.75%―――

* Healthcare Sector Average

Performance Comparison

-50%0%50%GB:APTAGB:AVCTGB:BVXPGB:OBDGB:FABGB:ARECDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:APTA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:APTAAptamer Group Plc0.28-0.65-69.35%
GB:AVCTAvacta Group plc59.00-13.50-18.62%
GB:BVXPBioventix plc1950.0045.252.38%
GB:OBDOxford BioDynamics0.10-0.18-62.50%
GB:FABFusion Antibodies Plc4.25-7.50-63.83%
GB:ARECArecor Therapeutics PLC71.50-2.50-3.38%

Aptamer Group Plc Corporate Events

Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing

Aptamer Group lifts revenue and cash as licensing and pharma demand deepen

Positive
Oct 13, 2026

Aptamer Group reported full-year revenue of £1.5 million, up 28% year-on-year, supported by growing demand for its Optimer technology and repeat work with multiple top 20 pharmaceutical companies. A £4.1 million equity raise lifted the year-end cash...

Business Operations and StrategyFinancial Disclosures

Aptamer Group Sets Analyst and Investor Meetings for Full-Year Results

Positive
Oct 7, 2026

Aptamer Group plc plans to release its full-year results for the period ended 30 June 2026 on 13 October, alongside a scheduled online briefing for analysts hosted by Chief Executive Dr Arron Tolley and Chief Financial Officer Andrew Rapson. The comp...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026